Germany’s Merck KGaA is finally nearing a roughly $3.5 billion deal for SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology ...

Germany's Merck KGaA has said it needs to double the productivity of its R&D operations, with the aim of launching a new product every 18 months on average, to boost its pharma business.

Merck will partner with Chinese biotech Abbisko ... expanding its commercialization rights for the drug beyond Asia. The German pharmaceutical company said Friday that it would pay Abbisko an ...

This integration builds trust in AI systems regarding data authenticity and origin,” said Thomas Endress, Head of M-Trust™, Merck KGaA, Darmstadt, Germany. “Our collaboration with Zebra ...

(Reuters) -Germany's Merck KGaA is nearing a roughly $3.5 billion deal for SpringWorks Therapeutics, the Wall Street Journal ...

Zebra Technologies Corporation (NASDAQ: ZBRA), a global leader in digitising and automating frontline workflows, and Merck KGaA, Darmstadt, Germany, a leading science and technology company ...